NCT04126811 is a Phase 2 clinical trial of Apatinib Mesylate, Pirarubicin, Ifosfamide in Soft Tissue Sarcoma, sponsored by Tianjin Medical University Cancer Institute and Hospital.

Who is sponsoring NCT04126811?

NCT04126811 is sponsored by Tianjin Medical University Cancer Institute and Hospital.

What drugs are being tested in NCT04126811?

Interventions in NCT04126811: Apatinib Mesylate, Pirarubicin, Ifosfamide, Apatinib Mesylate, Pirarubicin, Ifosfamide.

What condition does NCT04126811 study?

NCT04126811 studies Soft Tissue Sarcoma.

Is NCT04126811 still recruiting?

NCT04126811 is currently status unknown. Last updated 15 October 2019.

Last reviewed 2019-10-15 · How we verify

NCT04126811

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Apatinib Combined With Chemotherapy in the Treatment of Soft Tissue Sarcoma

Status unknown Phase 2 Last updated 15 October 2019

What this trial tests

Phase 2 trial testing Apatinib Mesylate, Pirarubicin, Ifosfamide in Soft Tissue Sarcoma in 120 participants. Status unknown.

Timeline

1 June 2019

Primary endpoint
31 December 2019

31 December 2020

Quick facts

Lead sponsor	Tianjin Medical University Cancer Institute and Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	120
Start date	1 June 2019
Primary completion	31 December 2019
Estimated completion	31 December 2020
Sites	1 location across China

Drugs / interventions tested

Apatinib Mesylate, Pirarubicin, Ifosfamide — full drug profile →
Apatinib Mesylate
Pirarubicin, Ifosfamide — full drug profile →

Conditions studied

Soft Tissue Sarcoma — all drugs for Soft Tissue Sarcoma →

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Who can join

Adults 14 to 75, any sex, with Soft Tissue Sarcoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To observe the efficacy of apatinib combined with AI regimen chemotherapy compared with AI regimen chemotherapy and single-agent apatinib in patients with unresectable soft tissue sarcoma. The main observations were progression-free survival (PFS) and progression-free control rate (PFR), followed by objective response rates (ORR, CR+PR), disease control rate (DCR, CR+PR+SD), and overall survival ( OS). To observe the safety of apatinib combined with AI chemotherapy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Clinical study of apatinib in the treatment of stage IV osteogenic sarcoma after failure of chemotherapy.
Liao Z, Li T, Zhang C, Liu X, et al · · 2020 · cited 12× · PMID 32587785 · DOI 10.20892/j.issn.2095-3941.2019.0397

Verify or expand the search:

Other recruiting trials for Soft Tissue Sarcoma

Currently open trials in the same condition.

NCT07261631 — Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors · Phase 1 · recruiting
NCT07243626 — Efficacy and Safety of Envafolimab Plus Doxorubicin and Ifosfamide for Advanced Soft Tissue Sarcoma · Phase 2 · recruiting
NCT07049848 — SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radi · Phase 2 · recruiting
NCT06962072 — Outcomes Following Limb Sparing Surgery for Soft Tissue Sarcoma · recruiting
NCT06905132 — Preoperative 5-Day Radiotherapy for Soft Tissue Sarcoma · Phase 2 · recruiting

Other Tianjin Medical University Cancer Institute and Hospital trials

Trials by the same sponsor.

NCT07493993 — Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoa · Phase 2 · not yet recruiting
NCT07515469 — A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD · Phase 2 · not yet recruiting
NCT07475026 — A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence · Phase 3 · not yet recruiting
NCT07510594 — A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC · Phase 2 · not yet recruiting
NCT07528274 — Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04126811 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tianjin Medical University Cancer Institute and Hospital
Last refreshed: 15 October 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04126811.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing